News > AI, Healthtech

BioXcel Pharmaceuticals CEO On Drug Pipeline, How AI Is Changing Sector

By Benzinga
AI, Healthtech

A biotech that’s using artificial intelligence to identify neuroscience and immuno-oncology medicines received FDA approval for an investigational new drug application this week, and Benzinga connected with its CEO for more insight on the company’s innovation efforts.

New Haven, Connecticut-based BioXcel Pharmaceuticals announced Monday that its IND was accepted by the FDA to initiate a clinical trial for the triple immuno-oncology combination of BXCL701, bempegaldesleukin and avelumab for the treatment of pancreatic cancer as a second-line therapy.

Read more at Benzinga.

Photo: Public Domain

Subscribe to our Newsletter

Be one of the first to experience the future of financial services